Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

P. Santus, D. Radovanovic, P. Paggiaro, A. Papi, A. Sanduzzi, N. Scichilone, F. Braido

Research output: Contribution to journalArticle

Abstract

Abstract Long-acting β2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β2-adrenoceptors availability, like in inflamed airways, a full agonist can maintain its bronchodilatory and non-smooth muscle activities while a partial agonist may be less effective. Furthermore, formoterol presents a faster onset of action than salmeterol. This phenomenon, combined with the molecule safety profile, leads to a prompt amelioration of the symptoms, and allows using this drug in asthma as an "as needed" treatment in patients already on regular treatment. The fast onset of action and the full agonism of formoterol need to be considered in order to select the best pharmacological treatment of asthma and COPD.

Original languageEnglish
Article number2924
Pages (from-to)379-384
Number of pages6
JournalEuropean Journal of Internal Medicine
Volume26
Issue number6
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Asthma
Adrenergic Receptors
Pharmacology
Therapeutics
Guidelines
Safety
Muscles
Formoterol Fumarate
Salmeterol Xinafoate
Pharmaceutical Preparations

Keywords

  • Asthma
  • Chronic obstructive pulmonary disease
  • Formoterol
  • LABA
  • Salmeterol

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol. / Santus, P.; Radovanovic, D.; Paggiaro, P.; Papi, A.; Sanduzzi, A.; Scichilone, N.; Braido, F.

In: European Journal of Internal Medicine, Vol. 26, No. 6, 2924, 01.07.2015, p. 379-384.

Research output: Contribution to journalArticle

Santus, P, Radovanovic, D, Paggiaro, P, Papi, A, Sanduzzi, A, Scichilone, N & Braido, F 2015, 'Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol', European Journal of Internal Medicine, vol. 26, no. 6, 2924, pp. 379-384. https://doi.org/10.1016/j.ejim.2015.05.001
Santus, P. ; Radovanovic, D. ; Paggiaro, P. ; Papi, A. ; Sanduzzi, A. ; Scichilone, N. ; Braido, F. / Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol. In: European Journal of Internal Medicine. 2015 ; Vol. 26, No. 6. pp. 379-384.
@article{272551c6aeb84ab5bb944709ff5de216,
title = "Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol",
abstract = "Abstract Long-acting β2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β2-adrenoceptors availability, like in inflamed airways, a full agonist can maintain its bronchodilatory and non-smooth muscle activities while a partial agonist may be less effective. Furthermore, formoterol presents a faster onset of action than salmeterol. This phenomenon, combined with the molecule safety profile, leads to a prompt amelioration of the symptoms, and allows using this drug in asthma as an {"}as needed{"} treatment in patients already on regular treatment. The fast onset of action and the full agonism of formoterol need to be considered in order to select the best pharmacological treatment of asthma and COPD.",
keywords = "Asthma, Chronic obstructive pulmonary disease, Formoterol, LABA, Salmeterol",
author = "P. Santus and D. Radovanovic and P. Paggiaro and A. Papi and A. Sanduzzi and N. Scichilone and F. Braido",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.ejim.2015.05.001",
language = "English",
volume = "26",
pages = "379--384",
journal = "European Journal of Internal Medicine",
issn = "0953-6205",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

AU - Santus, P.

AU - Radovanovic, D.

AU - Paggiaro, P.

AU - Papi, A.

AU - Sanduzzi, A.

AU - Scichilone, N.

AU - Braido, F.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Abstract Long-acting β2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β2-adrenoceptors availability, like in inflamed airways, a full agonist can maintain its bronchodilatory and non-smooth muscle activities while a partial agonist may be less effective. Furthermore, formoterol presents a faster onset of action than salmeterol. This phenomenon, combined with the molecule safety profile, leads to a prompt amelioration of the symptoms, and allows using this drug in asthma as an "as needed" treatment in patients already on regular treatment. The fast onset of action and the full agonism of formoterol need to be considered in order to select the best pharmacological treatment of asthma and COPD.

AB - Abstract Long-acting β2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β2-adrenoceptors availability, like in inflamed airways, a full agonist can maintain its bronchodilatory and non-smooth muscle activities while a partial agonist may be less effective. Furthermore, formoterol presents a faster onset of action than salmeterol. This phenomenon, combined with the molecule safety profile, leads to a prompt amelioration of the symptoms, and allows using this drug in asthma as an "as needed" treatment in patients already on regular treatment. The fast onset of action and the full agonism of formoterol need to be considered in order to select the best pharmacological treatment of asthma and COPD.

KW - Asthma

KW - Chronic obstructive pulmonary disease

KW - Formoterol

KW - LABA

KW - Salmeterol

UR - http://www.scopus.com/inward/record.url?scp=84939254544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939254544&partnerID=8YFLogxK

U2 - 10.1016/j.ejim.2015.05.001

DO - 10.1016/j.ejim.2015.05.001

M3 - Article

C2 - 26049917

AN - SCOPUS:84939254544

VL - 26

SP - 379

EP - 384

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

SN - 0953-6205

IS - 6

M1 - 2924

ER -